Eman Mohamed

Dr. Eman Mohamed

Rangel college of pharmacy, Texas A&M university
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SASogra F. Barakh Ali
Sogra F. Barakh Ali
EMEman Mohamed
Eman Mohamed
TOTanil Ozkan
Tanil Ozkan
MKMathew Abraham Kuttolamadom
Mathew Abraham Kuttolamadom
MKMansoor A. Khan
Mansoor A. Khan
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman

13 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SDSathish Dharani
Sathish Dharani
EMEman Mohamed
Eman Mohamed
TKTAHIR GANI KHUROO
TAHIR GANI KHUROO
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman
Mansoor A. KhanMansoor A. Khan
Mansoor A. Khan
The aim of this study was to improve the physicochemical properties and oral bioavailability of dasatinib (DST) by the amorphous solid dispersion (ASD) approach using cellulose acetate butyrate (CAB) as a carrier. Various formulations of ASD (DST:CAB 1:1 to 1:5) were prepared by the solvent evaporation method. ASDs were characterized for physicochemical attributes, stability and pharmacokinetics. Scanning electron microscopy, Fourier transformed infrared, X-ray powder diffraction, and differential scanning calorimetry confirmed the transformation of the crystalline drug into amorphous phase. ASD formation resulted in a 3.7–4.9 fold increase in dissolution compared to DST or physical mixture. The ASDs formulation exhibited relative stability against transformation from the unstable amorphous phase to a stable crystalline phase that was indicated by spectral and X-ray powder diffraction data, and insignificant (p > 0.05) decrease in dissolution. Tmax, Cmax and AUC0-∞ of ASD were 4.3-fold faster and 2.0 and 1.5 fold higher than the corresponding physical mixture. In conclusion, the ASD of DST significantly improved dissolution and oral bioavailability which may be translated into a reduction in dose and adverse events.

1 August 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
SASogra F. Barakh Ali
Sogra F. Barakh Ali
HAHamideh Afrooz
Hamideh Afrooz
RHRachel Hampel
Rachel Hampel
EMEman Mohamed
Eman Mohamed
RBRaktima Bhattacharya
Raktima Bhattacharya
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman

1 September 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TKTahir Khuroo
Tahir Khuroo
SDSathish Dharani
Sathish Dharani
EMEman Mohamed
Eman Mohamed
SISujana Immadi
Sujana Immadi
ZWZhixing Wu
Zhixing Wu
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman

9 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
EMEman Mohamed
Eman Mohamed
SDSathish Dharani
Sathish Dharani
MNMohammad T.H. Nutan
Mohammad T.H. Nutan
PCPhillip Cook
Phillip Cook
RARajendran Arunagiri
Rajendran Arunagiri
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman
The focus of the present work was to develop co-amorphous dispersion (CAD) formulations of tacrolimus (TAC) using sucrose acetate isobutyrate as a carrier, evaluate by in vitro and in vivo methods and compare its performance with hydroxypropyl methylcellulose (HPMC) based amorphous solid dispersion (ASD) formulation. CAD and ASD formulations were prepared by solvent evaporation method followed by characterization by Fourier transformed infrared spectroscopy, X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), dissolution, stability, and pharmacokinetics. XRPD and DSC indicated amorphous phase transformation of the drug in the CAD and ASD formulations, and dissolved more than 85% of the drug in 90 min. No drug crystallization was observed in the thermogram and diffractogram of the formulations after storage at 25 °C/60% RH and 40 °C/75% RH. No significant change in the dissolution profile was observed after and before storage. SAIB-based CAD and HPMC-based ASD formulations were bioequivalent as they met 90% confidence of 90–11.1% for Cmax and AUC. The CAD and ASD formulations exhibited Cmax and AUC 1.7–1.8 and 1.5–1.8 folds of tablet formulations containing the drug’s crystalline phase. In conclusion, the stability, dissolution, and pharmacokinetic performance of SAIB-based CAD and HPMC-based ASD formulations were similar, and thus clinical performance would be similar.

15 October 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EMEman Mohamed
Eman Mohamed
TKTAHIR GANI KHUROO
TAHIR GANI KHUROO
HAHamideh Afrooz
Hamideh Afrooz
SDSathish Dharani
Sathish Dharani
KSKhaldia Sediri
Khaldia Sediri
Ziyaur RahmanZiyaur Rahman
Ziyaur Rahman
The focus of the present investigation was to develop a predictive dissolution model for tablets coated with blends of cellulose acetate butyrate (CAB) 171-15 and cellulose acetate phthalate (C-A-P) using the design of experiment and chemometric approaches. Diclofenac sodium was used as a model drug. Coating weight gain (X1, 5, 7.5 and 10%) and CAB 171-15 percentage (X2, 33.3, 50 and 66.7%) in the coating composition relative to C-A-P and were selected as independent variables by full factorial experimental design. The responses monitored were dissolution at 1 (Y1), 8 (Y2), and 24 (Y3) h. Statistically significant (p < 0.05) effects of X1 on Y1 and X2 on Y1, Y2, and Y3 were observed. The models showed a good correlation between actual and predicted values as indicated by the correlation coefficients of 0.964, 0.914, and 0.932 for Y1, Y2, and Y3, respectively. For the chemometric model development, the near infrared spectra of the coated tablets were collected, and partial least square regression (PLSR) was performed. PLSR also showed a good correlation between actual and model predicted values as indicated by correlation coefficients of 0.916, 0.964, and 0.974 for Y1, Y2, and Y3, respectively. Y1, Y2, and Y3 predicted values of the independent sample by both approaches were close to the actual values. In conclusion, it is possible to predict the dissolution of tablets coated with blends of cellulose esters by both approaches.